{"id":"atropine-sulfate-02","safety":{"commonSideEffects":[{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Mydriasis and cycloplegia"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Confusion or agitation (at high doses)"},{"rate":null,"effect":"Hyperthermia"}]},"_chembl":{"chemblId":"CHEMBL1396281","moleculeType":"Small molecule","molecularWeight":"387.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atropine competitively antagonizes acetylcholine at muscarinic receptors throughout the body, reducing parasympathetic effects on the heart, smooth muscle, and secretory glands. This results in increased heart rate, bronchodilation, decreased secretions, and mydriasis. The sulfate salt formulation enhances solubility and bioavailability for parenteral or oral administration.","oneSentence":"Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:55.006Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anticholinergic poisoning and organophosphate/nerve agent exposure"},{"name":"Symptomatic bradycardia"},{"name":"Mydriasis and cycloplegia for ophthalmic examination"},{"name":"Preoperative antisialagogue"}]},"trialDetails":[{"nctId":"NCT06982092","phase":"PHASE1","title":"Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine.","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-08-26","conditions":"Perioperative Diaphragmatic Function","enrollment":60},{"nctId":"NCT05529056","phase":"PHASE3","title":"Study of Atropine Therapeutic Effect on Myopic Progression","status":"UNKNOWN","sponsor":"LitePharmTech Co., Ltd.","startDate":"2022-05-25","conditions":"Myopia, Children","enrollment":472}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":888,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LPTAT02"],"phase":"phase_3","status":"active","brandName":"Atropine Sulfate 02","genericName":"Atropine Sulfate 02","companyName":"LitePharmTech Co., Ltd.","companyId":"litepharmtech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atropine sulfate is an anticholinergic agent that blocks muscarinic acetylcholine receptors to inhibit parasympathetic nervous system activity. Used for Anticholinergic poisoning and organophosphate/nerve agent exposure, Symptomatic bradycardia, Mydriasis and cycloplegia for ophthalmic examination.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}